Search - tctmd.com

Presenter: Francesco Saia, William Wijns, Ran Kornowski, Patrick Joly, Fraser Witherow, Enrique Novo Garcia, Dezs? Apr?, Ismail Ates, Ernst G. Vester, Petr Kala, Sinan Dagdelen, Gian Battista Danzi

January 03, 2012

Presentation TCT 2012

New Generation Drug Eluting Stent Nobori: 2 Year Clinical Outcome of Patients with Chronic Total Occlusion.

Presenter: Bernard Chevalier, Dragan Sagic, Carlo Trani, Damras Tresukosol, Peep Laanmets, Mario Lombardi, Enrique Novo Garcia, Stefan Hoffmann, Harald Schwacke, Werner Jung, David Hildick-Smith, Gian Battista Danzi

January 03, 2012

Presentation TCT 2012

First Report of A Novel Polymer-Free Dual-Drug Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man BICARE Trial

Presenter: Mengyue Yu, Bo Xu, Yongjian Wu, Hongbing Yan, Jue Chen, Jie Qian, Chaowei Mu, Fenghuan Hu, Weixian Yang, Shubin Qiao, Yuejin Yang, Run-Lin Gao

January 03, 2012

Advertisement

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

TCTMD’s Top 10 Most Popular News Stories From 2011

Los Expertos Eligen los Avances Más Importantes de 2011

Los 10 Artículos Más Populares de TCTMD de 2011

Experts Give Their Picks for Most Important Developments of 2011

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

El Bloqueador de la Angiotensina Preserva la Función Endotelial Mejor que el Antagonista del Calcio

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

EVOLVE Published: Bioabsorbable EES Matches Permanent-Polymer Version

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Ensayo Aleatorizado Multicentro Comparador de Amfilimus con Stents Liberadores de Paclitaxel en Lesiones Coronarias Nativas De Novo

A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

SCAAR: Second-Generation DES Improve Hard Outcomes

Two Years Clinical Outcomes of Diabetic Patients Treated With a New Generation Drug-Eluting Stent.

New Generation Drug Eluting Stent Nobori: 2 Year Clinical Outcome of Patients with Chronic Total Occlusion.

First Report of A Novel Polymer-Free Dual-Drug Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man BICARE Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content